EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma

Upon the successful establishment of a battery of cellular models developing resistance to FGFR4 inhibitors, researchers identified the activation of EGFR, MAPK, and AKT signaling as the primary mechanisms mediating the acquired resistance.